Comparison of Treatment of Salmeterol and Formoterol with Fluticasone on Quality of Life (QOL) of Patients Suffering from Chronic Obstructive Pulmonary Disease (COPD)

Simple item page
dc.contributor.authorKumar, Sanjeeven_US
dc.contributor.authorMatreja, Prithpal Sen_US
dc.contributor.authorKhanna, P M Len_US
dc.date.accessioned2019-11-16T07:23:37Z
dc.date.available2019-11-16T07:23:37Z
dc.date.issued2017-04
dc.description.abstractBackground: Chronic obstructive pulmonary disease (COPD) is characterized by symptoms of dyspnoea, paroxysmal coughing, fatigue, and insomnia associated with considerable impact on quality of life of patients. Inhaled corticosteroid/long-acting β2-agonist combinations (ICS/LABA) are endorsed for maintenance therapy for COPD.  So, we designed this study to compare the treatment of combination of salmeterol or formoterol with fluticasone on Quality of life (QOL) of patients suffering from chronic obstructive pulmonary disease (COPD). Methods: This prospective, randomized, parallel group study was conducted 45 patients suffering from COPD were enrolled in the study after they signed a written informed consent. The patients were divided in two groups based on the treatment in two groups. Group 1 was on treatment with salmeterol with fluticasone whereas group 2 was on treatment with formoterol with fluticasone; they were assessed at baseline and 4weeks. Patients were subjected to St George Respiratory Questionnaire (SGRQ) and WHO – Quality of life (WHO-QOL Bref) Questionnaire. Results: A total of 24 patients in group 1 and 21 patients in group 2 completed the study. The demographic profile of patients was comparable at baseline. Patients in both groups had showed a statistically significant improvement in symptoms score as compared to baseline as is evident by lower scores in SGRQ and high scores in WHO-QOL Bref score Patients on formoterol and fluticasone had slightly better scores as compared to the other group though it was not statistically significant. Conclusions: Both the treatment showed significant improvement in symptoms as well as quality of life as compared to baseline and a combination of formoterol and fluticasone was slightly better as compared to combination of salmeterol and fluticasone.en_US
dc.identifier.affiliationsAssociate Professor, Department of Pulmonary Medicine, Himalayan Institute of Medical Sciences, Dehradun, 248140en_US
dc.identifier.affiliationsProfessor & HOD, Department of Pharmacology, Teerthanker Mahaveer Medical College & Research Center, Moradabad, 244001en_US
dc.identifier.affiliationsProfessor & Head, Department of Pharmacology, Gian Sagar Medical College and Hospital, Village Ram Nagar, District Patiala, Punjab, India-1406013en_US
dc.identifier.citationKumar Sanjeev, Matreja Prithpal S, Khanna P M L. Comparison of Treatment of Salmeterol and Formoterol with Fluticasone on Quality of Life (QOL) of Patients Suffering from Chronic Obstructive Pulmonary Disease (COPD). International Archives of BioMedical and Clinical Research. 2017 Apr-Jun; 3(2): 37-40en_US
dc.identifier.issn2454-9894
dc.identifier.issn2454-9886
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/184119
dc.languageenen_US
dc.publisherIbn Sina Academy of Medieval Medicine & Sciencesen_US
dc.relation.issuenumber2en_US
dc.relation.volume3en_US
dc.source.urihttps://doi.org/10.21276/iabcr.2017.3.2.8en_US
dc.subjectChronic Obstructive Pulmonary Diseaseen_US
dc.subjectQuality of lifeen_US
dc.subjectpatientsen_US
dc.subjectsymptomsen_US
dc.titleComparison of Treatment of Salmeterol and Formoterol with Fluticasone on Quality of Life (QOL) of Patients Suffering from Chronic Obstructive Pulmonary Disease (COPD)en_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
iabcr2017v3n2p37.pdf
Size:
563.79 KB
Format:
Adobe Portable Document Format
Download
Collections
International Archives of BioMedical and Clinical Research